Hokuriku Pharmaceutical announced that its holding subsidiary Haichang Pharmaceutical has received the “Notice of Approval of Application for the Marketing of Chemical Ingredients” for iopromide approved and issued by the State Drug Administration. Iopromide is the raw material for contrast iopromide injections and is used for CT enhancement and other contrast tests. The approval of this API will further enrich Haichang Pharmaceutical's raw materials, enhance market competitiveness, promote sales business growth, and create favorable conditions for the company to expand its competitive advantage and market share in the field of contrast agents.

Zhitongcaijing · 07/01 09:25
Hokuriku Pharmaceutical announced that its holding subsidiary Haichang Pharmaceutical has received the “Notice of Approval of Application for the Marketing of Chemical Ingredients” for iopromide approved and issued by the State Drug Administration. Iopromide is the raw material for contrast iopromide injections and is used for CT enhancement and other contrast tests. The approval of this API will further enrich Haichang Pharmaceutical's raw materials, enhance market competitiveness, promote sales business growth, and create favorable conditions for the company to expand its competitive advantage and market share in the field of contrast agents.